Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Net Margin (2016 - 2025)

Historic Net Margin for Sunshine Biopharma (SBFM) over the last 8 years, with Q3 2025 value amounting to 3.14%.

  • Sunshine Biopharma's Net Margin rose 173400.0% to 3.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.06%, marking a year-over-year increase of 6600.0%. This contributed to the annual value of 14.72% for FY2024, which is 39800.0% up from last year.
  • Per Sunshine Biopharma's latest filing, its Net Margin stood at 3.14% for Q3 2025, which was up 173400.0% from 31.36% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Net Margin ranged from a high of 783.75% in Q4 2021 and a low of 15440.43% during Q1 2021
  • Over the past 5 years, Sunshine Biopharma's median Net Margin value was 22.49% (recorded in 2024), while the average stood at 1651.22%.
  • Data for Sunshine Biopharma's Net Margin shows a peak YoY increase of 144324500bps (in 2022) and a maximum YoY decrease of -13805400bps (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Net Margin stood at 783.75% in 2021, then crashed by -176bps to 596.78% in 2022, then skyrocketed by 97bps to 16.28% in 2023, then crashed by -38bps to 22.49% in 2024, then soared by 114bps to 3.14% in 2025.
  • Its Net Margin stands at 3.14% for Q3 2025, versus 31.36% for Q2 2025 and 13.25% for Q1 2025.